2022 Jiangsu medical insurance dual-channel drug list

Hello! Glad to answer for you! 2022 Jiangsu medical insurance dual-channel drug list. Hello, dear, 2022 Jiangsu medical insurance dual-channel drug list: 1. Six kinds of drugs, such as trastuzumab injection, bevacizumab injection, adalimumab injection, retiqu injection, erlotinib oral sustained-release dosage form and deslorazex oral sustained-release dosage form, were transferred out of the list of separate payment for drugs, and a consistent medical insurance treatment policy was implemented with reference to "dual-channel" management and separate payment for drugs for the time being. Two, the national medical insurance negotiation drug list of etoposa ethanolamine tablets into the "dual channel" management and separate payment directory. Three. Ectinib hydrochloride tablets in the national medical insurance negotiation drug list were changed from "dual-channel" management to "dual-channel" management and separate payment list. Four, adjust the scope of drugs including generic drugs and similar drugs with the same generic name and dosage form in the medical insurance catalogue. Five, municipal medical insurance agencies should update the relevant information in the database of basic medical insurance, work-related injury insurance and maternity insurance drugs in our city, medical insurance agencies at all levels should do a good job in policy convergence and handling service management, and all designated medical institutions should do a good job in patient communication and explanation to ensure a balanced transition of policies.